Kotani, Haruru http://orcid.org/0000-0002-0355-9294
Masuda, Norikazu http://orcid.org/0000-0002-7302-0278
Yamashita, Toshinari http://orcid.org/0000-0002-6479-1660
Naito, Yoichi http://orcid.org/0000-0002-8490-9064
Taira, Tetsuhiko http://orcid.org/0000-0002-3091-8168
Inoue, Kenichi http://orcid.org/0000-0003-2686-8732
Takahashi, Masato http://orcid.org/0000-0002-6641-9598
Yonemori, Kan
Toyoizumi, Shigeyuki http://orcid.org/0000-0002-7011-5263
Mori, Yuko http://orcid.org/0000-0003-1919-2463
Nagasawa, Takashi http://orcid.org/0000-0002-1600-1062
Hori, Natsuki http://orcid.org/0000-0003-4675-3975
Iwata, Hiroji
Clinical trials referenced in this document:
Documents that mention this clinical trial
Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study
https://doi.org/10.1007/s12282-022-01390-w
Funding for this research was provided by:
Pfizer
Article History
Received: 27 April 2022
Accepted: 10 July 2022
First Online: 30 July 2022
Declarations
:
: Haruru Kotani has no disclosures to report. Norikazu Masuda reports honoraria from AstraZeneca, Chugai, Eisai, Eli Lilly, and Pfizer; research funding to their institution from AstraZeneca, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, Kyowa Kirin, MSD, Novartis, Pfizer, and Sanofi; and is on the board of directors for the Japanese Breast Cancer Society and JBCRG (Japan Breast Cancer Research Group Association). Toshinari Yamashita reports research funding to their institution from Chugai, Kyowa Kirin, Nippon Kayaku, and Taiho; and honoraria from AstraZeneca, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, Kyowa Kirin, Nippon Kayaku, Novartis Pharma, Pfizer Japan, and Taiho. Yoichi Naito reports participation in the speaker’s bureau for AstraZeneca, Bayer, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Eli Lilly, Nippon Kayaku, Novartis, Pfizer, Roche Diagnostics, and Taiho; and research funding from Roche Diagnostics. Tetsuhiko Taira reports honoraria from Chugai, Daiichi Sankyo, Eli Lilly, Kyowa Kirin, Novartis, and Taiho. Kenichi Inoue reports honoraria from Chugai; and research funding to their institution from AstraZeneca, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, MSD, Pfizer, and Sanofi. Masato Takahashi reports honoraria from AstraZeneca, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, and Pfizer; and research funding to their institution from Kyowa Kirin and Taiho. Kan Yonemori reports honoraria from AstraZeneca, Chugai, Eisai, Eli Lilly, Pfizer, and Takeda; advisor fees from Chugai, Eisai, Novartis, Ono, and Takeda; and research funding to their institution from AstraZeneca, Boehringer Ingelheim, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, Genmab, Kyowa Kirin, Taiho, Takeda, MSD, Nihon-Kayaku, Novartis, Pfizer, and Sanofi. Shigeyuki Toyoizumi, Yuko Mori, Takashi Nagasawa, and Natsuki Hori report salary and ownership interest for Pfizer. Hiroji Iwata reports research funding from Chugai, Lilly, MSD, and Novartis; honoraria from AstraZeneca, Chugai, and Daiichi Sankyo; and participation in advisory boards for AstraZeneca, Chugai, Daiichi Sankyo, Kyowa Hakko Kirin, Lilly, Novartis, and Pfizer.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.